Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, aciclovir lauriad (Sitavig®) cannot be endorsed for use within NHS Wales for the treatment of recurrent herpes labialis in immunocompetent adults with frequent herpes episodes. |
||
|
||
Medicine details |
||
| Medicine name | aciclovir lauriad (Sitavig®) | |
| Formulation | 50 mg buccal tablet | |
| Reference number | 1501 | |
| Indication | Treatment of recurrent herpes labialis in immunocompetent adults with frequent herpes episodes. |
|
| Company | BioAlliance Pharma | |
| BNF chapter | Infections | |
| Submission type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Date of issue | 29/07/2013 | |